FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P13
Within normal range
vs 2Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -11.15% |
| Q3 2025 | -17.60% |
| Q2 2025 | -10.98% |
| Q1 2025 | 16.77% |
| Q4 2024 | 10.14% |
| Q3 2024 | -4.89% |
| Q2 2024 | -9.68% |
| Q1 2024 | 45.87% |
| Q4 2023 | 15.26% |
| Q3 2023 | -4.20% |
| Q2 2023 | -13.49% |
| Q1 2023 | 86.34% |
| Q4 2022 | -3.42% |
| Q3 2022 | 45.18% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |